C-3VDJepigenetic editing, genetic tuning, TEMPO
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Evaluate Tune-401 for adults with chronic hepatitis B, including safety, tolerability, pharmacokinetics, and pharmacodynamics.
Phase 1b open-label clinical study in adult participants with chronic hepatitis B.
Phase 1b clinical trial listed as NCT06671093, published 2024-11-29.
Control gene activity by dialing gene expression up or down without cutting or altering DNA, with potential applications across rare genetic disorders, common chronic diseases, and age-related diseases.
Proprietary epigenetic editing/genetic tuning platform intended to modulate gene expression without DNA sequence alteration.
Company describes TEMPO as its proprietary platform and lists Tune-401 as a pipeline program associated with its genetic tuning approach.